ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

This study is testing a treatment called immune tolerance induction (ITI) — using a clotting factor product called SCT800, with or without the drug daratumumab — to help the immune system stop attacking clotting factors in people with severe hemophilia A who have developed inhibitors (antibodies that block their treatment from working). **You may be eligible if...** - You are between 14 and 66 years old - You have moderate or severe hemophilia A - You have developed inhibitors (tested positive on two separate visits) - Your inhibitor level is above 10 BU at screening **You may NOT be eligible if...** - You are allergic to any of the drug ingredients or to hamster-derived proteins - You have another immune disorder or are taking immunosuppressive drugs for another condition - You have previously failed a full course of immune tolerance induction therapy - Your level of compliance with treatment is expected to be poor Talk to your doctor to see if this trial is right for you.